Cargando…

Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer

BACKGROUND: With this study, we sought to characterise the impact of pro-inflammatory cytokines on the outcomes of gemcitabine monotherapy (GEM) in patients with pancreatic cancer (PC). METHODS: Treatment-naive patients with advanced PC and no obvious infections were eligible for enrolment. All of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mitsunaga, S, Ikeda, M, Shimizu, S, Ohno, I, Furuse, J, Inagaki, M, Higashi, S, Kato, H, Terao, K, Ochiai, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670479/ https://www.ncbi.nlm.nih.gov/pubmed/23591198 http://dx.doi.org/10.1038/bjc.2013.174

Ejemplares similares

Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer
por: Eto, K, et al.
Publicado: (2013)

CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone
por: Wasan, H S, et al.
Publicado: (2009)

Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin
por: Bafna, S, et al.
Publicado: (2009)

Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia
por: Maftouh, M, et al.
Publicado: (2014)

Role of IL-12p40 in cervical carcinoma
por: Zijlmans, H J M A A, et al.
Publicado: (2012)

DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer
por: Drouillard, A, et al.
Publicado: (2016)

Early Growth Response 3 regulates genes of inflammation and directly activates IL6 and IL8 expression in prostate cancer
por: Baron, V T, et al.
Publicado: (2015)

Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer
por: Michalski, C W, et al.
Publicado: (2008)

Leptin pro-angiogenic signature in breast cancer is linked to IL-1 signalling
por: Zhou, W, et al.
Publicado: (2011)

Inflammatory cytokine IL-8/CXCL8 promotes tumour escape from hepatocyte-induced dormancy
por: Khazali, Ahmad S, et al.
Publicado: (2018)

Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo
por: Gassler, N, et al.
Publicado: (2005)

Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis
por: Xue, A, et al.
Publicado: (2010)

Increased circulating cell signalling phosphoproteins in sera are useful for the detection of pancreatic cancer
por: Takano, S, et al.
Publicado: (2010)

IL-22 produced by cancer-associated fibroblasts promotes gastric cancer cell invasion via STAT3 and ERK signaling
por: Fukui, H, et al.
Publicado: (2014)

Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial–mesenchymal transition in ovarian carcinomas
por: Colomiere, M, et al.
Publicado: (2009)

Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer
por: Kawaguchi, T, et al.
Publicado: (2013)

Prognostic utility of HOXB13 : IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial
por: Jerevall, P-L, et al.
Publicado: (2011)

Serum apolipoprotein C-II is prognostic for survival after pancreatic resection for adenocarcinoma
por: Xue, A, et al.
Publicado: (2012)

Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer
por: Morimura, R, et al.
Publicado: (2011)

Circulating IL-6 concentrations link tumour necrosis and systemic and local inflammatory responses in patients undergoing resection for colorectal cancer
por: Guthrie, G J K, et al.
Publicado: (2013)

VEPH1 expression decreases vascularisation in ovarian cancer xenografts and inhibits VEGFA and IL8 expression through inhibition of AKT activation
por: Shathasivam, Premalatha, et al.
Publicado: (2017)

iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance
por: Tonack, S, et al.
Publicado: (2013)

Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer
por: Boeck, S, et al.
Publicado: (2013)

Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags
por: Sogawa, Kazuyuki, et al.
Publicado: (2016)

Serum total hCGβ level is an independent prognostic factor in transitional cell carcinoma of the urothelial tract
por: Douglas, J, et al.
Publicado: (2014)

Serum oestrogen receptor α and β bioactivity are independently associated with breast cancer: a proof of principle study
por: Widschwendter, M, et al.
Publicado: (2009)

Oral squamous cell carcinoma patients can be differentiated from healthy individuals with label-free serum proteomics
por: Saraswat, Mayank, et al.
Publicado: (2017)

Plasma microRNA profiles: identification of miR-744 as a novel diagnostic and prognostic biomarker in pancreatic cancer
por: Miyamae, Mahito, et al.
Publicado: (2015)

Poly(A) RT–PCR measurement of diagnostic genes in pancreatic juice in pancreatic cancer
por: Oliveira-Cunha, M, et al.
Publicado: (2011)

Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia
por: Moniaux, N, et al.
Publicado: (2008)

Upregulation of cancer-associated myofibroblasts by TGF-β from scirrhous gastric carcinoma cells
por: Fuyuhiro, Y, et al.
Publicado: (2011)

Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma
por: Takeshita, N, et al.
Publicado: (2013)

Fibroblast inhibition by tocilizumab enabled gemcitabine/nab‐paclitaxel rechallenge for pancreatic cancer
por: Mitsunaga, Shuichi, et al.
Publicado: (2023)

Fucosylated TGF-β receptors transduces a signal for epithelial–mesenchymal transition in colorectal cancer cells
por: Hirakawa, M, et al.
Publicado: (2014)

Methyl-CpG-binding domain 3 inhibits epithelial–mesenchymal transition in pancreatic cancer cells via TGF-β/Smad signalling
por: Xu, Min, et al.
Publicado: (2017)

Endostatin expression in pancreatic tissue is modulated by elastase
por: Brammer, R D, et al.
Publicado: (2005)

miR-367 promotes epithelial-to-mesenchymal transition and invasion of pancreatic ductal adenocarcinoma cells by targeting the Smad7-TGF-β signalling pathway
por: Zhu, Z, et al.
Publicado: (2015)

PIAS4 is an activator of hypoxia signalling via VHL suppression during growth of pancreatic cancer cells
por: Chien, W, et al.
Publicado: (2013)

Promoter CpG methylation in cancer cells contributes to the regulation of MUC4
por: Yamada, N, et al.
Publicado: (2009)

Tumour epithelial vimentin expression and outcome of pancreatic ductal adenocarcinomas
por: Handra-Luca, A, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_gfma674lcg9trhc6rkt5kkjfvm